18 MONTH A1C AND WEIGHT OUTCOMES OF EXENATIDE THERAPY IN PATIENTS WITH TYPE-2 DIABETES IN A REAL-WORLD STUDY

被引：2
|
作者：
Brixner, D. [1 ]
McAdam-Marx, C. [1 ]
Ye, X. [1 ]
Misurski, D. [2 ]
Wintle, M. [3 ]
Fabunmi, R. [3 ]
机构：
[1] Univ Utah, Coll Pharm, Salt Lake City, UT 84112 USA
[2] Eli Lilly & Co, Indianapolis, IN 46285 USA
[3] Amylin Pharmaceut Inc, San Diego, CA USA
来源：
VALUE IN HEALTH | 2009年 / 12卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)73550-6
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A97 / A97
页数：1
相关论文
共 50 条
  • [1] A1C and weight outcomes at 18 months in patients with type 2 diabetes treated with exenatide in an ambulatory care setting
    McAdam-Marx, C.
    Ye, X.
    Brixner, D. I.
    Fabunmi, R.
    Wintle, M.
    Boye, K. S.
    Misurski, D.
    Nielsen, L. L.
    DIABETES OBESITY & METABOLISM, 2009, 11 (12): : 1173 - 1174
  • [2] Combination therapy with insulin glargine and exenatide: real-world outcomes in patients with type 2 diabetes
    Levin, Philip
    Wei, Wenhui
    Wang, Li
    Pan, Chunshen
    Douglas, Damon
    Baser, Onur
    CURRENT MEDICAL RESEARCH AND OPINION, 2012, 28 (03) : 439 - 446
  • [3] Real-World Comparison of Oral Versus Injectable Semaglutide for the Reduction of Hemoglobin A1C and Weight in Patients with Type 2 Diabetes
    Pinto, Maria
    Brennan, Lillian
    Diehl, Katie
    Lin, Shally
    Heacock, Samantha
    JOURNAL OF PHARMACY TECHNOLOGY, 2025, 41 (01) : 22 - 31
  • [4] REAL-WORLD' CLINICAL OUTCOMES OF EXENATIDE BID COMPARED TO INSULIN GLARGINE IN PATIENTS WITH TYPE 2 DIABETES
    Pawaskar, M.
    Li, Q.
    Hoogwerf, B.
    Reynolds, M. W.
    Faries, D. E.
    Bruhn, D.
    Bergenstal, R.
    VALUE IN HEALTH, 2011, 14 (07) : A475 - A475
  • [5] Real-world Impact of 3 and 4.5 mg Doses of Dulaglutide on Weight and Hemoglobin A1c in Patients With Type 2 Diabetes Mellitus
    Duong, Amy
    Heacock, Samantha
    Amering, Sarah
    Brennan, Lillian
    Venci, Jineane
    Acquisto, Nicole M.
    ANNALS OF PHARMACOTHERAPY, 2024, 58 (06) : 589 - 597
  • [6] Real-world clinical outcomes and predictors of glycaemic and weight response to exenatide once weekly in patients with type 2 diabetes: The CIBELES project
    Jose Gorgojo-Martinez, Juan
    Angel Gargallo-Fernandez, Manuel
    Brito-Sanfiel, Miguel
    Lisbona-Catalan, Arturo
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2018, 72 (03)
  • [7] Real World Clinical Experience with Exenatide, a Long Term Study on Weight and A1c Control
    Houser, Dana
    Christofides, Elena A.
    DIABETES, 2011, 60 : A618 - A618
  • [8] Real World Clinical Experience with Exenatide, a Long Term Study on Weight and A1c Control
    Christofides, Elena A.
    Boyle, Patrick J.
    Johnson, Michele T.
    DIABETES, 2009, 58 : A154 - A154
  • [9] Six-month outcomes on A1C and cardiovascular risk factors in patients with type 2 diabetes treated with exenatide in an ambulatory care setting
    Brixner, D. I.
    McAdam-Marx, C.
    Ye, X.
    Boye, K. S.
    Nielsen, L. L.
    Wintle, M.
    Misurski, D.
    Fabunmi, R.
    DIABETES OBESITY & METABOLISM, 2009, 11 (12): : 1122 - 1130
  • [10] Predictors of Glycemic and Weight Response to Exenatide Once-Weekly in Patients with Type 2 Diabetes in a Real-World Setting
    Gorgojo-Martinez, Juan J.
    Brito-Sanfiel, Miguel A.
    Gargallo-Fernandez, Manuel A.
    Lisbona-Catalan, Arturo
    DIABETES, 2017, 66 : A297 - A297
12345